ATYR aTYR PHARMA INC
Price Chart
Executive Summary
aTyr Pharma reported Q1 2026 net loss of $10.8M ($0.11/share), narrower than the prior year, and ended the quarter with $68.3M cash. The company reiterated its plan to submit an IND in June 2026 for a Phase 3 study of efzofitimod in pulmonary sarcoidosis following constructive FDA feedback, providing a clear regulatory path forward.
Actionable Insight
The FDA clarity and planned IND submission de-risk the lead program; monitor June 2026 IND filing and any additional pipeline updates. The narrower loss and stable cash position provide runway into 2027.
Key Facts
- Q1 2026 net loss attributable to aTyr was $10.8M ($0.11/share) vs $14.9M ($0.17/share) in Q1 2025
- Cash, cash equivalents, restricted cash and investments: $68.3M as of March 31, 2026
- R&D expenses decreased to $7.3M from $11.8M year-over-year
- Plans to submit IND in June 2026 for a new Phase 3 study of efzofitimod in pulmonary sarcoidosis with restrictive lung disease
- Phase 2 EFZO-CONNECT study enrollment on track to complete in first half 2026
Financial Impact
Net loss improved by 27.5% year-over-year; cash burn $15.6M in Q1 2026 vs $14.1M in Q4 2025
Risk Factors
- Clinical trial failure of efzofitimod in Phase 3
- Cash burn may require future dilutive financing
- Regulatory delays or additional FDA requirements
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001339970-26-000030 |
| Document: atyr-20260515.htm | 0001339970-26-000030 |
| Document: 0001339970-26-000030-index-headers.html | 0001339970-26-000030 |
| Document: 0001339970-26-000030-index.html | 0001339970-26-000030 |
| Document: 0001339970-26-000030.txt | 0001339970-26-000030 |
| 8-K Data (Synthetic) | 0001339970-26-000030 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
1d ago
|
Institutional Cluster
| $0.4591 awaiting T+1 | awaiting T+1 | — | $0.4400 (−4.16%) |
|
Jun 8, 2026
4d ago
|
8-K
| $0.4430 awaiting T+1 | awaiting T+1 | — | $0.4400 (+0.68%) |
|
Jun 1, 2026
11d ago
|
8-K
| $0.5200 $0.5001 | ▼ −3.83% | ▼ −3.13% | $0.4400 (−15.38%) |
|
May 15, 2026
28d ago
|
8-K
| $0.5040 $0.5200 | ▲ +3.17% | ▲ +3.24% | $0.4400 (−12.70%) |
|
May 15, 2026
29d ago
|
Press Release
| $0.5040 $0.5200 | ▲ +3.17% | ▲ +3.24% | $0.4400 (−12.70%) |
|
May 11, 2026
4w ago
|
8-K
| $0.5300 $0.5300 | · 0.00% | ▼ −0.54% | $0.4400 (−16.98%) |
|
Mar 26, 2026
11w ago
|
DEFA14A
| $0.7520 $0.7310 | ▼ −2.79% | ▼ −2.43% | $0.4400 (−41.49%) |
|
Mar 5, 2026
14w ago
|
8-K
| $0.8240 $0.9000 | ▲ +9.22% | ▲ +8.38% | $0.4400 (−46.60%) |
|
Mar 5, 2026
14w ago
|
Press Release
| $0.8240 $0.9000 | ▲ +9.22% | ▲ +8.38% | $0.4400 (−46.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access